USSTOCK.TODAY
Regular Market
Log in Sign up

Revolution Medicines beats revenue estimates with RASONQUE launch

Earnings Whispers +3 · ·by G4L

RVMD Revolution Medicines Inc
$200.15 +4.09%
View chart & analysis →
  1. 1Revolution Medicines recorded $197,560,000 in net product sales for RASONQUE during the approximately five weeks following FDA approval on August 26.
  2. 2This represents a 596.1% revenue surprise, exceeding the Revolution Medicines consensus revenue estimate of $28,380,000.
  3. 3Management told investors that third-quarter results should not be viewed as an indicator of the long-term trajectory.

So what's the key point?

Sales from a newly launched drug by Revolution Medicines were much higher than experts expected. The company stated that these results should not be used as a benchmark for future performance.

Source Earnings Whispers +3 · View original ↗

Related 3-line summaries

Revolution Medicines Receives FDA Approval for Pancreatic Cancer Treatment, Raising Royalty Pharma Revenue Expectations The Motley Fool +1 · yesterdayRevolution Medicines Receives Pancreatic Cancer Treatment Approval and Increases Stake The Motley Fool +1 · Oct 29Revolution Medicines Obtains US Approval for Pancreatic Cancer Treatment Razonc The Motley Fool +2 · Oct 28
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news